top of page

What is IPIC? 

 

The International Post-operative Intravesical Chemotherapy Study - Multi-centre Qualitative analysis of guideline adherence of peri-operative intravesical chemotherapy in non-muscle invasive bladder cancer

Contact Details and registration:  ipic.yuro@gmail.com

 

  • Lead investigator: Dr Tatenda Nzenza

  • Overall Recruitment Officer (RO): Dr Simeon Ngweso

  • East coast RO: Dr Catriona Duncan

  • Public relations: Dr Todd Manning

  • IT: Dr Shannon McGrath

 

 

Study Objectives

​

  • To investigate rate of use of post-operative intravesical chemotherapy for non-muscle invasive bladder cancer (NIMBC)

  • To assess guideline compliance rate, patterns of use and barriers to use of intravesical chemotherapy for NMIBC

 

Aim

​

  • Multi-centre retrospective audit of post-operative chemotherapy use for NIMBC

  • Across Australia, New Zealand, Canada and UK

  • All patients who underwent TURBT for suspected NIMBC in 2016

  • RedCaps Database

 

Inclusion Criteria

​

  • Age >18 yrs

  • TURBT

  • As defined by operation note: Lesion suspected to be low grade at time of procedure (Ta/1), completely resected solitary papillary tumour

​

Exclusion Criteria

​

  • Age <18 years

  • High grade bladder cancer, CIS, multifocal (>1) or >3cm

  • Currently receiving ongoing intravesical chemotherapy

 

 

 

Recruitment closes 1st March 2018 - Register NOW!

bottom of page